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Abstract 
The mitochondrial calcium uniporter (MCU) transports free ionic Ca2+ into the mitochondrial 
matrix. We assessed MCU expression in clinical breast cancer samples using microarray 
analysis and the consequences of MCU silencing in a breast cancer cell line. Our results 
indicate that estrogen receptor negative and basal-like breast cancers are characterized by 
elevated levels of MCU. Silencing of MCU expression in the basal-like MDA-MB-231 breast 
cancer cell line produced no change in proliferation or cell viability. However, distinct 
consequences of MCU silencing were seen on cell death pathways. Caspase-dependent cell 
death initiated by the Bcl-2 inhibitor ABT-263 was not altered by MCU silencing; whereas 
caspase-independent cell death induced by the calcium ionophore ionomycin was 
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potentiated by MCU silencing. Measurement of cytosolic Ca2+ levels showed that the 
promotion of ionomycin-induced cell death by MCU silencing occurs independently of 
changes in bulk cytosolic Ca2+ levels. This study demonstrates that MCU overexpression is a 
feature of some breast cancers and that MCU overexpression may offer a survival advantage 
against some cell death pathways. MCU inhibitors may be a strategy to increase the 
effectiveness of therapies that act through the induction of caspase-independent cell death 
pathways in estrogen receptor negative and basal-like breast cancers. 
Highlights 
• Some clinical breast cancers are associated with MCU overexpression. 
• MCU silencing did not alter cell death initiated with the Bcl-2 inhibitor ABT-263. 
• MCU silencing potentiated caspase-independent cell death initiated by ionomycin 
• MCU silencing promoted ionomycin-mediated cell death without changes in bulk Ca2+ 
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1. Introduction  
Mitochondria regulate numerous cellular processes and are vital for both sustaining cell 
survival and the initiation of cell death [1, 2]. The uptake of Ca2+ by mitochondria can buffer 
increases in cytosolic free Ca2+ ([Ca2+]CYT) and stimulate specific mitochondrial functions 
such as ATP synthesis [1, 2]. Mitochondrial Ca2+ levels may also influence sensitivity to cell 
death activators [3, 4]. In malignant transformation, remodeling of Ca2+ homeostasis and 
reprogramming of mitochondrial functions could confer cancer cells with a survival 
advantage and an ability to evade cell death [5, 6]. Calcium transporters including the 
voltage-dependent anion-selective channel (VDAC) and the mitochondrial Ca2+ uniporter 
(MCU) [1] participate in mitochondrial Ca2+ uptake and have been proposed as potential 
regulators of cell death [7, 8].  
Since the molecular identification of MCU [9, 10], several studies have investigated the 
significance of mitochondrial Ca2+ uptake on specific cellular processes through the 
modulation of MCU expression levels. In cardiomyocytes MCU silencing amplifies bulk 
[Ca2+]CYT and is associated with increased contractile responses [11]. In breast cancer cells 
sustained increases of bulk [Ca2+]CYT are associated with the promotion of cell death 
responses [12]. However, the potential for MCU to modulate cell death and other events in 
breast cancer cells has not been investigated. 
MCU has been studied in other cancer types. One recent study identified MCU down-
regulation as a characteristic feature of some human colon and prostate cancer cells [13]. 
Down-regulation of MCU in colon and prostate-derived cancers promotes increased 
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proliferation and bestows resistance to cell death stimuli through diminished mitochondrial 
Ca2+ levels [13]. No studies have yet assessed MCU in the context of breast cancer.  
In this study we assessed MCU expression in clinical breast cancers and evaluated the 
functional significance of MCU silencing on proliferation, cell death pathways and on bulk 
[Ca2+]CYT in MDA-MB-231 breast cancer cells. Our results suggest that MCU inhibition may 
sensitize some breast cancers to some inducers of cell death. 
2. Materials and Methods 
2.1. Analysis of MCU levels in human breast cancer cases 
Gene expression data for 180 human breast cancer cases [14] were obtained from NCBI-GEO 
(Accession GSE3165) and imported into Partek Genomics Suite (version 6.6). MCU 
(annotated on these microarrays as C10orf42) expression was analyzed in samples grouped 
by both estrogen receptors status and PAM50 molecular subtype [15]. 
2.2. Cell culture 
Human MDA-MB-231 breast cancer cells (American Type Culture Collection) were grown 
in high glucose DMEM (Sigma Aldrich) supplemented with 10% FBS and 4 mM L-
glutamine (Invitrogen) at 37 °C/5% CO2 in a humidified air incubator.  
2.3. Silencing of MCU expression 
MDA-MB-231 cells were transfected as previously described [12] with ON-TARGETplusTM 
SMARTpool siRNAs (Dharmacon), consisting of four pooled siRNA sequences rationally 
designed to minimize off-target effects [16, 17]. The specific siRNAs used in this study were 
MCU siRNA (siMCU, L-015519-02) and the non-targeting control siRNA (siNT, D-001810-
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10).  For all experiments MCU mRNA silencing (>70%) was confirmed at 48 h post-siRNA. 
2.4. Quantitative real time RT-PCR 
Quantitative real time RT-PCR was performed as described previously [12]. Briefly, at 48 or 
120 h post siRNA-transfection total RNA was isolated (RNeasy Plus mini kit; Qiagen), and 
then reverse transcribed (Omniscript RT kit; Qiagen). The cDNA of interest were amplified 
using the TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and TaqMan Gene 
Expression assays (MCU, Hs00293548_m1; 18 S rRNA, 4319413E; Applied Biosystems) 
under universal cycling conditions with a StepOnePlus real time PCR system (Applied 
Biosystems). MCU mRNA levels were quantified by the comparative Ct method as described 
[18] normalized to 18 S rRNA and presented relative to the siNT control. 
2.5. Cell enumeration and S-phase analysis 
MDA-MB-231 cells were transfected with siRNA for 120 h and then cell enumeration and S-
phase analysis were performed as previously described [19]. Briefly, cells with newly 
synthesized DNA were stained, according to the manufacturer’s instructions using the Click-
iT® EdU cell proliferation assay (Alexa Fluor 555; Invitrogen). DAPI-stained cell nuclei 
(400 nM; 90 min) and EdU-positive cells were imaged with a 10× objective using an 
ImageXpress Micro automated epifluorescence microscope (Molecular Devices Corporation) 
[20]. Cell number and percentage of EdU positive cells were calculated using the multi-
wavelength cell scoring application module (MetaXpress v3.1.0.83; Molecular Devices). 
2.6. Assessment of cell viability 
At 72 h post siRNA-transfection MDA-MB-231 cells were treated with the cell death 
activators ABT-263 (Selleckchem), ionomycin (Enzo Life Sciences), or with dimethyl 
 6 
sulfoxide (up to 0.33%) and incubated for an additional 48 h. Cell viability was then assessed 
in non-fixed cells as previously reported by evaluating Hoechst 33342 (10 µg/mL; 
Invitrogen) and propidium iodide (1 µg/mL; Invitrogen) staining [12]. Imaging was 
performed using an ImageXpress Micro automated epifluorescence microscope (Molecular 
Devices Corporation). Criteria for viable and propidium iodide positive cells (PI+) were 
defined as previously described [12].  
2.7. Cytosolic free Ca2+ measurements 
At 72 h post siRNA-transfection MDA-MB-231 breast cancer cells were loaded with either a 
high Ca2+ affinity (Fluo-4AM (4 µM; Molecular Probes)) or a low Ca2+ affinity (Fluo-4FF (4 
µM; Molecular Probes)) Ca2+ indicator according to published methods [12]. [Ca2+]CYT was 
then monitored using a fluorescence imaging plate reader [21] (Molecular Devices 
Corporation) as previously described [12]. To assess relative [Ca2+]CYT fluorescence was 
normalized to base-line values.  
2.8. Statistical analysis 
Statistical tests were performed as described in the figure legends using GraphPad Prism 
version 5.04 for Windows. 
3. Results 
3.1. MCU mRNA levels in clinical breast cancer samples  
Assessment of MCU mRNA levels in a cohort of 180 breast cancer cases [14] showed a 
significantly (P < 0.05; Fig. 1A) higher level of MCU in estrogen receptor (ER)-negative 
breast cancers. When breast cancers were stratified by molecular subtype the highest levels of 
MCU were seen in basal-like breast cancers (P < 0.05; basal-like versus luminal A and B 
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subtypes; Fig. 1B), while other subtypes expressed intermediated MCU levels (Fig. 1B). ER-
negative and basal-like breast cancers are associated with a particularly poor prognosis [22, 
23]. 
3.2. Effects of MCU silencing on proliferation and cell viability in MDA-MB-231 breast 
cancer cells  
To assess the possible role of MCU overexpression in breast cancer, we used specific siRNAs 
to silence MCU expression in basal-like MDA-MB-231 breast cancer cells [24]. Compared to 
the siNT control, cells transfected with siMCU showed a significant (P < 0.05) decrease in 
MCU mRNA levels at 48 h (Fig. 2A) and 120 h (Fig. 2B) post-siRNA. Using this model we 
assessed the effects of MCU knockdown on proliferation and cell viability.  
Effects of MCU silencing on cell proliferation were evaluated by cell enumeration and S-
phase analysis (EdU staining). MCU silencing did not significantly alter cell number (Fig. 
2C), or the percentage of cells in S-phase (EdU positive; Fig. 2D) compared to the siNT 
control. Cell viability was also quantified; MCU silencing had no significant effect on the 
percentage of viable cells compared to the siNT control (Fig. 2E-G). 
3.3. MCU silencing sensitizes MDA-MB-231 breast cancer cells to ionomycin-mediated cell 
death 
To analyze whether MCU silencing regulates breast cancer cell responses to death activators, 
siRNA-transfected MDA-MB-231 cells were treated with the Ca2+ ionophore ionomycin to 
initiate caspase-independent cell death [12]. Compared to the siNT control MCU silencing 
potentiated sub-maximal ionomycin (3 µM)-mediated cell death, with a significant (P < 0.05) 
reduction in cell viability and a marked (P < 0.05) increase in the proportion of propidium 
iodide positive cells (Fig. 3A).  Silencing of MCU did not alter cell viability at a higher 
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ionomycin concentration (10 µM) compared to the siNT control (Fig. 3B). These data suggest 
MCU silencing sensitizes MDA-MB-231 cells to caspase-independent cell death initiated 
with ionomycin. 
3.4. MCU silencing does not modulate ABT-263-mediated MDA-MB-231 breast cancer cell 
death  
The Bcl-2 inhibitor ABT-263 was used to address the consequence of MCU silencing on 
caspase-dependent cell death in the MDA-MB-231 breast cancer cell line [12]. Compared 
with the siNT control, MCU silencing exerted no effect on cell death initiated at either the 
submaximal (3 µM; Fig. 3C) or high (10 µM; Fig. 3D) ABT-263 concentrations. This 
suggests that MCU knockdown does not sensitize MDA-MB-231 cells to caspase-dependent 
cell death initiated by ABT-263.  
3.5. Effects of MCU silencing on increases in bulk [Ca2+]CYT  
To assess whether MCU silencing modified the nature of bulk [Ca2+]CYT increases, we 
challenged siRNA-transfected MDA-MB-231 breast cancer cells with different initiators of  
[Ca2+]CYT increases. Moderate increases in bulk [Ca2+]CYT were induced with the sarco-
endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor cyclopiazonic acid (CPA; 10 µM) or 
the protease activated receptor activator trypsin (0.1 µM) under Ca2+-free conditions. 
Compared with the siNT control, silencing of MCU did not alter either CPA (Fig. 4A) or 
trypsin (Fig. 4C) Ca2+ responses, with no significant difference detected for area under the 
curve  (Fig. 4B&D) or other Ca2+ transient parameters such as peak [Ca2+]CYT and half peak 
decay time (data not shown). 
A role for MCU in shaping Ca2+ signals of higher magnitude was evaluated in the presence of 
extracellular Ca2+ (2 mM) using the Ca2+ ionophore ionomycin. Assessment of [Ca2+]CYT 
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with the low affinity Ca2+ indicator Fluo-4FF, showed that MCU silencing compared to the 
siNT control had no major effects on bulk [Ca2+]CYT increases, at either submaximal (3 µM; 
Fig. 4E-F) or high (10 µM; Fig. 4G-H) ionomycin concentrations. Collectively, these 
findings demonstrate that MCU does not have a major role in the regulation of bulk [Ca2+]CYT 
in MDA-MB-231 breast cancer cells. 
4. Discussion  
A previous study identified MCU downregulation in prostate and colon-derived cancers [13], 
here we present data showing that MCU is upregulated in some clinical breast cancer 
subtypes. MCU was most highly expressed in ER-negative and basal-like breast cancers both 
of which are associated with a poor prognosis [22, 23]. To understand the implication of 
MCU overexpression in breast cancer, we assessed the functional consequences of MCU 
silencing on proliferation, cell death and bulk [Ca2+]CYT in the basal-like MDA-MB-231 
breast cancer cell line.  
Our silencing studies in MDA-MB-231 cells showed MCU knockdown had no effect on 
proliferation or cell viability. However, assessment of MCU knockdown on cell death 
initiated by ABT-263 and ionomycin defined a distinct role for MCU in the regulation of 
caspase-independent and -dependent cell death pathways, respectively. MCU silencing did 
not affect ABT-263-mediated cell death, but acted as a sensitizer of cell death initiated with 
ionomycin. MCU silencing attenuates mitochondrial Ca2+ uptake [9, 10] and reduced 
mitochondrial Ca2+ levels act to suppress cell death in a variety of malignant cell lines, 
including those derived from the cervix [4] central nervous system [25], head and neck [26] 
and lymph [27] tissues. We therefore hypothesized that MCU knockdown in MDA-MB-231 
breast cancer cells would also protect from death insults. However, MCU knockdown did not 
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protect against ABT-263-induced cell death, and potentiated ionomycin-initiated cell death.  
Alterations in bulk [Ca2+]CYT signals were examined as a potential mechanism of MCU 
silencing-mediated promotion of ionomycin-initiated cell death.  In cardiomyocytes MCU 
silencing amplifies cytosolic Ca2+ signals [11] and we have recently shown sustained 
increases of bulk [Ca2+]CYT are associated with the promotion of ionomycin-mediated MDA-
MB-231 cell death [12]. However, our assessment of bulk [Ca2+]CYT showed no major 
changes upon MCU knockdown on Ca2+ signals stimulated with CPA, trypsin or ionomycin. 
These data suggest that MCU does not significantly contribute in buffering global cytosolic 
free Ca2+; therefore increases in bulk [Ca2+]CYT are unlikely to explain the promotion of 
ionomycin-initiated cell death upon MCU silencing. 
The ability of MCU silencing to sensitize MDA-MB-231 cells to ionomycin-mediated cell 
death could be due to diminished mitochondrial Ca2+ uptake and alterations in the autophagy 
survival pathway, as the specific MCU inhibitor Ru360 regulates autophagy in HEK293 and 
DT40 cells [28]. Another mechanism may involve alterations in localized Ca2+ signals within 
specialized signaling domains at the endoplasmic reticulum-mitochondrial interface, known 
as mitochondrial-associated-membranes (MAMs) [29]. A recent study investigated reduced 
mitochondrial Ca2+ uptake through knockdown of the MAM-enriched calcium transporter, 
VDAC1 [30]. VDAC1 silencing potentiates the response of human-derived HeLa cervical 
cancer cells to death activators without affecting bulk [Ca2+]CYT, this sensitization was not 
dependent on diminished mitochondrial Ca2+ levels [30]. Localized Ca2+ signals possibly 
within MAM domains may represent another regulatory site for Ca2+-dependent death signals 
in breast cancer cells and along with MCU-mediated regulation of autophagy requires further 
investigation. 
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In this report, we have identified MCU overexpression in some clinical breast cancers, in 
particular those subtypes associated with a poor prognosis (estrogen receptor negative and 
basal-like). MCU silencing in the basal-like MDA-MB-231 breast cancer cell line promoted 
ionomycin-initiated but not ABT-263-mediated cell death. MCU inhibitors may therefore 
represent novel therapies for some breast cancers by potentiating some caspase-independent 
cell death mechanisms. 
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Figure Legends 
Fig. 1. MCU expression in clinical breast cancers is associated with estrogen receptor status 
and molecular subtype. Relative MCU levels were analyzed in human breast cancer cases (n 
= 180) stratified by (A) estrogen receptor (ER) status and (B) molecular subtype. MCU levels 
were highest in ER-negative tumors (P < 0.05, Mann-Whitney test) and showed the strongest 
enrichment in the basal-like subtype (P < 0.05; basal-like versus Luminal A and B, Kruskall-
Wallis test with Dunn’s post-test for multiple comparisons). 
Fig. 2. MCU silencing in MDA-MB-231 cells and the effects of silencing on proliferation 
and cell viability. MCU was silenced in MDA-MB-231 cells using siRNA and the effects on 
cell number, S-phase and cell viability were compared to the siNT control. Relative MCU 
mRNA levels at (A) 48 h and (B) 120 h post-transfection with siMCU or siNT. Effects of 
MCU knockdown on (C) average cell number, (D) percentage S-phase (EdU-positive cells) 
and (G) percentage viable cells. Bar graphs show the mean ± S.D obtained from three 
independent experiments (n=3) performed in triplicate. Dot plots show changes in cell 
viability with either (E) siNT or (F) siMCU for 10,000 cells randomly selected from three 
independent experiments (n=3) performed in triplicate wells. *P < 0.05, paired two-tailed t 
test. 
Fig. 3. Consequences of MCU silencing on ionomycin- and ABT-263-initiated cell death in 
MDA-MB-231 cells. MCU was silenced in MDA-MB-231 cells using siRNA and then cells 
were treated with (A) 3 µM ionomycin, (B) 10 µM ionomycin, (C) 3 µM ABT-263 or with 
(D) 10 µM ABT-263 for 48 h prior to cell death assessment. Bar graphs show mean ± SD of 
the proportion of viable and propidium iodide positive (PI+) cells in siMCU and siNT 
 15 
transfected cells. Data were obtained from three independent experiments (n=3) performed in 
triplicate. *P < 0.05, repeated measures two-way ANOVA, Bonferroni post-hoc analysis. 
Fig. 4. Effect of MCU silencing on bulk [Ca2+]CYT increases stimulated by various initiators 
of [Ca2+]CYT increases. (A) CPA (10 µM)-mediated and (C) trypsin (0.1 µM)-induced 
[Ca2+]CYT transients measured with the Ca2+ indicator Fluo-4AM after transfection with 
siMCU or siNT in the presence of extracellular BAPTA (100 µM). (E) 3 µM ionomycin and 
(G) 10 µM ionomycin [Ca2+]CYT transients recorded using the Ca2+ indicator Fluo-4FF in 
cells transfected with siNT or siMCU. Bar graphs show the mean ± S.D for the area under the 
curve calculated for the (B) 10 µM CPA, (D) 0.1 µM trypsin, (F) 3 µM ionomycin and (H) 10 
µM ionomycin [Ca2+]CYT increases. Ca2+ traces represent relative mean fluorescence. All data 
were obtained from three independent experiments (n=3) performed in triplicate. *P < 0.05, 
paired two-tailed t test. 
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Figure 3 
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